Errata to FDA Briefing Document

Oncologic Drugs Advisory Committee Meeting

December 17, 2019

NDA 208558/Supplement 10
Lynparza (olaparib) tablets
AstraZeneca

Errata to FDA Briefing Document
ODAC Meeting
December 17, 2019

This document is an errata to the original FDA Briefing Document. The erroneous text is followed by the correction in bold below.

1. Page 4, Section 2 Executive Summary, text below:

   This is an important consideration since 60% and 80% of patients with disease progression in the olaparib and placebo arms, respectively, were identified solely or in part based on progressive disease in the pancreas.

   Corrected to read as:

   This is an important consideration since **38% and 50%** of patients with disease progression in the olaparib and placebo arms, respectively, were identified solely or in part based on progressive disease in the pancreas.

2. Page 17, Section 4.2.1 Study Population, text below:

   At the time of the final PFS analysis based on a January 30, 2019 data cut-off date, a total of 154 patients (92 in olaparib arm and 62 in placebo arm) were randomized.

   Corrected to read as:

   At the time of the final PFS analysis based on a **January 15, 2019** data cut-off date, a total of 154 patients (92 in olaparib arm and 62 in placebo arm) were randomized.

3. Page 18, Table 2 Study Population, text below:

Demographic Group	Olaparib 300 mg twice daily N=92 (%)	Placebo twice daily N=62 (%)
Age		
< 65	64 (70)	49 (79)
≥ 65	28 (30)	13 (21)
Sex		
Female	39 (42)	31 (50)
Male	53 (58)	31 (50)
Race		
White	82 (90)	59 (95)
Asian	4 (4.3)	2 (3.2)
Black or African-American	5 (5.4)	0
Other	1 (1.1)	1 (1.7)
Region		
North America	21 (23)	12 (21)
Western Europe	49 (54)	39 (61)
Middle East (Israel)	17 (16)	8 (12)
Asia (Korea)	4 (4.4)	2 (3.3)
Other	1 (1.1)	1 (1.6)
ECOG Performance Status (baseline)		
0	65 (71)	38 (61)
1	25 (27)	23 (37)
Missing	2 (2.2)	1 (1.6)

Corrected to read as:

Demographic Group	Olaparib 300 mg twice daily N=92 (%)	Placebo twice daily N=62 (%)
Age		
< 65	64 (70)	49 (79)
≥ 65	28 (30)	13 (21)
Sex		
Female	39 (42)	31 (50)
Male	53 (58)	31 (50)
Race		
White	82 (90)	59 (95)
Asian	4 (4.3)	2 (3.2)
Black or African-American	5 (5.4)	0
Other	1 (1.1)	1 (1.7)
Region		
North America	**22 (24)**	**13 (21)**
Western Europe	49 (54)	39 (61)
Middle East (Israel)	**16 (17)**	**7 (11)**
Asia (Korea)	4 (4.4)	2 (3.3)
Other	1 (1.1)	1 (1.6)
ECOG Performance Status (baseline)		
0	65 (71)	38 (61)
1	25 (27)	23 (37)
Missing	2 (2.2)	1 (1.6)

4. Page 26, Table 7 Study POLO Safety Overview (Safety Analysis Set), text below:

	Olaparib 300 mg twice daily N=91 (%)	**Placebo twice daily N=60 (%)**
Median Exposure	6 months	4 months
Patient with ≥ 1 AE	87 (95)	56 (93)
Patients with Grade 3-5 AE	36 (39)	14 (23)
Patients with SAE	22 (24)	9 (15)
Deaths not due to progression	4 (4.4)	1 (1.7)
Treatment discontinuation due to AE	4 (4.4)	1 (1.7)
Dose modifications due to AE	33 (36)	4 (6)

AE= adverse events; SAE= serious adverse events

Corrected to read as:

	Olaparib 300 mg twice daily N=91 (%)	**Placebo twice daily N=60 (%)**
Median Exposure	6 months	4 months
Patient with ≥ 1 AE	87 (95)	56 (93)
Patients with Grade 3-5 AE	36 (39)	14 (23)
Patients with SAE	22 (24)	9 (15)
Deaths not due to progression	**2 (2.2)**	**0**
Treatment discontinuation due to AE	4 (4.4)	1 (1.7)
Dose modifications due to AE	33 (36)	4 (6)

AE= adverse events; SAE= serious adverse events

5. Page 26, Table 8 Adverse Reactions in POLO in ≥10% of patients, text below:

	Olaparib 300 mg twice daily N=91[a]		Placebo twice daily N=60[a]	
	All Grades (%)	Grades 3–4 (%)	All Grades (%)	Grades 3–4 (%)
General Disorders and Administration Site Conditions				
Fatigue	42 (46)	4 (4.4)	19 (32)	0
Asthenia	15 (16)	1 (1.1)	5 (8)	1 (1.7)
Pyrexia	12 (13)	0	5 (8)	0
Peripheral edema	8 (9)	1 (1.1)	7 (12)	0
Blood and Lymphatic System Disorders				
Anemia	25 (27)	11 (12)	10 (17)	2 (3.3)
Gastrointestinal Disorders				
Nausea	42 (46)	0	15 (25)	1 (1.7)
Abdominal pain[b]	32 (35)	1 (1.1)	25 (42)	0
Diarrhea	26 (29)	0	9 (15)	0
Constipation	22 (24)	0	7 (12)	0
Vomiting	18 (20)	1 (1.1)	11 (18)	1 (1.7)
Dyspepsia	5 (5.5)	0	6 (10)	0
Abdominal distension	4 (4.4)	0	6 (10)	0
Metabolism and Nutrition Disorders				
Decreased appetite	23 (25)	3 (3.3)	5 (8)	0
Skin and Subcutaneous Tissue Disorders				
Rash[c]	12 (13)	0	3 (5)	0
Pruritis	10 (11)	0	4 (7)	0
Respiratory, Thoracic and Mediastinal Disorders				
Dyspnea	10 (11)	0	3 (5)	1 (1.7)
Nervous System Disorders				
Peripheral neuropathy	10 (11)	1 (1.1)	7 (12)	0
Dysgeusia	10 (11)	0	3 (5)	0
Headache	6 (7)	0	8 (13)	0
Musculoskeletal and Connective Tissue Disorders				
Back pain	18 (20)	0	12 (20)	1 (1.7)
Arthralgia	14 (15)	1 (1.1)	6 (10)	0
Infections and Infestations				

	Olaparib 300 mg twice daily N=91[a]		Placebo twice daily N=60[a]	
	All Grades (%)	Grades 3–4 (%)	All Grades (%)	Grades 3–4 (%)
Nasopharyngitis	11 (12)	0	2 (3.3)	0

[a] Three randomized patients did not receive treatment (two in the olaparib arm and one in the placebo arm). One patient who was randomized to the placebo arm received olaparib and is included here in the olaparib group.
[b] Includes abdominal pain, abdominal pain lower, abdominal pain upper, abdominal discomfort
[c] Includes preferred terms of rash and rash erythematous

Corrected to read as:

	Olaparib 300 mg twice daily N=91[a]		Placebo twice daily N=60[a]	
	All Grades (%)	Grades 3–4 (%)	All Grades (%)	Grades 3–4 (%)
General Disorders and Administration Site Conditions				
Fatigue	**41 (45)**	4 (4.4)	**16 (27)**	0
Asthenia	15 (16)	1 (1.1)	5 (8)	1 (1.7)
Pyrexia	12 (13)	0	5 (8)	0
~~Peripheral edema~~	~~8 (9)~~	~~1 (1.1)~~	~~7 (12)~~	~~0~~
Gastrointestinal Disorders				
Nausea	**41 (45)**	0	**14 (23)**	1 (1.7)
Abdominal Pain[b]	**31 (34)**	**2 (2.2)**	**22 (37)**	**3 (5)**
Diarrhea	26 (29)	0	9 (15)	0
Constipation	**21 (23)**	0	**6 (10)**	0
Vomiting	18 (20)	1 (1.1)	**9 (15)**	1 (1.7)
~~Dyspepsia~~	~~5 (5.5)~~	~~0~~	~~6 (10)~~	~~0~~
Abdominal distension	4 (4.4)	0	6 (10)	0
Blood and Lymphatic System Disorders				
Anemia	25 (27)	**10 (11)**	10 (17)	2 (3.3)
Metabolism and Nutrition Disorders				
Decreased appetite	23 (25)	3 (3.3)	**4 (7)**	0
Musculoskeletal and Connective Tissue DIsorders				
Back pain	**17 (19)**	0	**10 (17)**	1 (1.7)
Arthralgia	14 (15)	1 (1.1)	6 (10)	0

	Olaparib 300 mg twice daily N=91[a]		Placebo twice daily N=60[a]	
	All Grades (%)	Grades 3–4 (%)	All Grades (%)	Grades 3–4 (%)
Skin and Subcutaneous Tissue				
Rash[c]	12 (13)	0	3 (5)	0
~~Pruritis~~	~~10 (11)~~	~~0~~	~~4 (7)~~	~~0~~
Infections and Infestations				
Nasopharyngitis	11 (12)	0	2 (3.3)	0
Respiratory, Thoracic and Mediastinal Disorders				
Dyspnea	10 (11)	0	3 (5)	1 (1.7)
Nervous System Disorders				
Dysgeusia	10 (11)	0	3 (5)	0
Peripheral neuropathy	**7 (8)**	1 (1.1)	7 (12)	0
Headache	6 (7)	0	8 (13)	0

[a] Three randomized patients did not receive treatment (two in the olaparib arm and one in the placebo arm). One patient who was randomized to the placebo arm received olaparib and is included here in the olaparib group.
[b] Includes abdominal pain, abdominal pain lower, abdominal pain upper~~, abdominal discomfort~~
[c] Includes preferred terms of rash and rash erythematous